Pharmalot... Pharmalittle... Good Morning

Good morning, everyone, and welcome to another working week. This should be a busy one, especially as the big JP Morgan conference gets under way. As always, there is much to do, so grab a cup of stimulation and start digging in. To help you along, we have gathered a few tidbits - and we do update this list each day - and will be working to get a few stories ready shortly. Hope your day goes well and do stay in touch...

Roche Chair Says Illumina Bid Is Off The Table (Reuters)

Biotech CEOs See Insurers As The New Obstacle (Xconomy)

J&J Faces First Vaginal Mesh Implant Trial (Bloomberg News)

Dr. Reddy's Acquires 80 Percent Of OctoPlus (Economic Times)

Alkermes Aims For Psychiatric Drug Without Weight Gain (Xconomy)

Exela To Expand North Carolina Plant (Winston Salem-Journal)

EDITOR'S NOTE: Please check this post for updates

morning coffee pic thx to chichacha on flickr

1 Comment

Jan 7, 2013 - 10:43am
A former company of mine worked with Lilly to develop the concept of a combination of olanzapine and an anorectic but never took it to trial. I have no doubt that Lilly holds at least a use patent on such a combination that Alkermes would have to confront.